Haemophilia and associated bleeding disorders are chronic conditions that require easy, accessible, and reliable venous access for treatment. Peripheral venous access is traditionally the first option considered for prophylaxis. The initial introduction of prophylaxis to a child is during the first two years of life, and peripheral access can be problematic. Central venous catheters (CVC), for example port-a-caths, are widely used among this group; however, these devices require surgical insertion and are not without their own complications. Data were collected on venous access methods used at the paediatric centre at the Evelina London Children’s Hospital, where 242 children are registered at the comprehensive care centre, 48 of whom have a severe bleeding disorder. Of these 48, 27 have a CVC currently (PICC n=1, Port-a-Cath n=25, Hickman line n=1) and 3 have an arteriovenous fistula (AVF). Patient 1 is a 12 year-old boy with severe haemophilia A and an intracranial haemorrhage at the age of 9 months. He remains on prophylaxis and had an AVF created 5 years ago following repeated port-a-cath infections and poor venous access. Patient 2 is a 7 year-old boy with severe haemophilia B and an inhibitor, who has also had repeated port-a-cath infections. An AVF was constructed 2 years ago. Patient 3 is a 12 year-old girl with type III von Willebrand disease and an inhibitor. Due to need for regular factor treatment in the context of poor venous access, an AVF was formed. We have had a 100% success rate with all three AVFs at a follow-up period of 8-69 months. Our experience suggests AVF is a viable option of venous access in patients with haemophilia and other bleeding disorders, especially so for children with repeated CVC infections or poor peripheral venous access. However, this is not a straightforward option and further evidence on long-term use based on multicentre research will be beneficial in managing AVF in this group of patients.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients: a long-term follow-up. J Intern Med 1997; 24: 395-40.
2. Fischer K, Collins PW, Ozelo MC, Srivastsva A, Young G, Blanchette VS. When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. J Thromb Haemost 2016; 14: 1105-9.
3. Komvilaisak P, Connolly B, Naqvi A, Blanchette V. Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders. Haemophilia 2006; 12(6): 87-93.
4. McCarthy MJ, Valentino LA, Bonilla AS, Goncharova I, Taylor A, Pooley TA, Jacobs CE. Arteriovenous fistula for long-term venous access for boys with hemophilia. J Vasc Surg 2006; 45(5): 986-90.
5. Santagostino E, Mancuso ME. Venous access in haemophilic children: choice and management. Haemophilia 2010; 16(1): 20-24.
6. Mancuso ME, Berardinelli L. Arteriovenous fistula as a stable venous access in children with severe haemophilia. Haemophilia 2010; 16(1): 25-28.
7. Santagostino E, Gringeri A, Berardinelli L, Beretta C, Muca-Perja M, Mannucci PM. Long-term safety and feasibility of arteriovenous fistulas as vascular accesses in children with haemophilia: a prospective study. Br J Haematol 2003; 123(3): 502-6.
8. Manscuso ME, Berardinelli L, Beretta C, Raiteri M, Pozzoli E, Santagostino E. Improved treatment feasibility in children with hemophilia using artiovenous fistulae: the follow-up. Haematologica 2009; 94(5): 687-92.
9. Chand DH, Valentini RP, Kamil ES. Hemodialysis vascular access options in pediatric: considerations for patients and practionners. Int J Pediatr 2009; 24(6): 1121-8.
10. Wartman S, Rose D, Woo K, Gradman W, Weaver FA, Rowe V. Outcomes with arteriovenous fistulas in the pediatric population. J Vasc Surg 2014; 60(1): 170-5.
11. Carslen CG, Taylor SM, Cull D, Langan EM, Snyder BA, Yonky JR, Caldwell RA. AV fistula: a forgotten alternative to venous access. Ann Vas Surg 2004; 18(6): 635-9.
12. Stovroff M, Teague WG. Intravenous access in infants and children. Pediatr Clin North Am 1998; 45(6): 1373-93.
13. Heibl C, Trommet V, Burgstaller S, Mayrbaeurl B, Baldinger C, Koplmuller R, Kuhr T, Wimmer L, Thaler J. Complications associated with the use of. Port-a Caths in patients with malignant or haematological disease: a single centre prospective analysis. Eur J Cancer Care 2009; 19(5): 676-81.
14. Santagostino E, Mancuso ME. Barriers to primary prophylaxis in haemophilic children: the issue of the venous access. Blood Transfus 2008; 6(2): 12-16.
15. Lok CE. Fistula first initiative: advantages and pitfalls. Clin J Am Soc Nephrol 2007; 2(5): 1043-53.
16. Al-Jaishi AA, Oliver OJ, Thomas SM, Lok CE, Zhang JC, Garg AX, Kosa S, Quinn RR, Moist LM. Patency rates of the arteriovenous fistula for hemodialysis: a systematic review and meta-analysis. Am J Kidney Dis 2014; 63(3): 464-78.
17. Khair K, Baker K. Therapeutic use of arteriovenous fistula in children with haemophilia http://www.ncbi.nlm.nih.gov/pubmed/19057498 Br J Nur 2008; 17(22): 1396-400.
18. Almási-Sperling V, Galiano M, Lang W, Rother U, Rascher W, Regus S. Timing of first arteriovenous fistula cannulation in children on hemodialysis. Pediatr Nephrol. 2016 Apr 25 [Epub ahead of print].